Opus Genetics IRD
NASDAQ IRD
$4.58 +0.07 (+1.55%)
At close: Oct 2, 2026 · 4:00 PM EDT

Opus Genetics (IRD) Gains from Sales and Divestitures (2019)

Updated

Opus Genetics (IRD) recorded Gains from Sales and Divestitures of -$9,594 in FY2019.

Analysis

Opus Genetics (IRD) Gains from Sales and Divestitures (2019) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Opus Genetics 378.53 Mn 153.81 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2019 -9,594.00
API Access

Opus Genetics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=IRD&period=max&api_key=YOUR_API_KEY